<?xml version='1.0' encoding='utf-8'?>
<document id="24509406"><sentence text="Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia."><entity charOffset="94-103" id="DDI-PubMed.24509406.s1.e0" text="lesinurad" /><entity charOffset="108-118" id="DDI-PubMed.24509406.s1.e1" text="febuxostat" /><pair ddi="false" e1="DDI-PubMed.24509406.s1.e0" e2="DDI-PubMed.24509406.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24509406.s1.e0" e2="DDI-PubMed.24509406.s1.e1" /></sentence><sentence text="The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout"><entity charOffset="103-112" id="DDI-PubMed.24509406.s2.e0" text="lesinurad" /><entity charOffset="124-133" id="DDI-PubMed.24509406.s2.e1" text="uric acid" /><entity charOffset="178-188" id="DDI-PubMed.24509406.s2.e2" text="febuxostat" /><entity charOffset="190-198" id="DDI-PubMed.24509406.s2.e3" text="xanthine" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e0" e2="DDI-PubMed.24509406.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e0" e2="DDI-PubMed.24509406.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e0" e2="DDI-PubMed.24509406.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e0" e2="DDI-PubMed.24509406.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e1" e2="DDI-PubMed.24509406.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e1" e2="DDI-PubMed.24509406.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e1" e2="DDI-PubMed.24509406.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e2" e2="DDI-PubMed.24509406.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24509406.s2.e2" e2="DDI-PubMed.24509406.s2.e3" /></sentence><sentence text="" /><sentence text="This study was a phase IB, multicentre, open-label, multiple-dose study of gout patients with serum uric acid (sUA) &gt;8 mg/dl following washout of urate-lowering therapy with colchicine flare prophylaxis"><entity charOffset="100-109" id="DDI-PubMed.24509406.s4.e0" text="uric acid" /><entity charOffset="111-114" id="DDI-PubMed.24509406.s4.e1" text="sUA" /><entity charOffset="146-151" id="DDI-PubMed.24509406.s4.e2" text="urate" /><entity charOffset="174-184" id="DDI-PubMed.24509406.s4.e3" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e0" e2="DDI-PubMed.24509406.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e0" e2="DDI-PubMed.24509406.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e0" e2="DDI-PubMed.24509406.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e0" e2="DDI-PubMed.24509406.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e1" e2="DDI-PubMed.24509406.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e1" e2="DDI-PubMed.24509406.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e1" e2="DDI-PubMed.24509406.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e2" e2="DDI-PubMed.24509406.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24509406.s4.e2" e2="DDI-PubMed.24509406.s4.e3" /></sentence><sentence text=" Febuxostat 40 or 80 mg/day was administered on days 1-21, lesinurad 400 mg/day was added on days 8-14 and then lesinurad was increased to 600 mg/day on days 15-21" /><sentence text=" sUA, urine uric acid and PK profiles were evaluated at the end of each week"><entity charOffset="12-21" id="DDI-PubMed.24509406.s6.e0" text="uric acid" /><entity charOffset="1-9" id="DDI-PubMed.24509406.s6.e1" text="sUA" /><pair ddi="false" e1="DDI-PubMed.24509406.s6.e1" e2="DDI-PubMed.24509406.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24509406.s6.e1" e2="DDI-PubMed.24509406.s6.e0" /></sentence><sentence text=" Safety was assessed by adverse events, laboratory tests and physical examinations" /><sentence text="" /><sentence text="Initial treatment with febuxostat 40 or 80 mg/day monotherapy resulted in 67% and 56% of subjects, respectively, achieving a sUA level &lt;6 mg/dl"><entity charOffset="23-33" id="DDI-PubMed.24509406.s9.e0" text="febuxostat" /><entity charOffset="125-134" id="DDI-PubMed.24509406.s9.e1" text="sUA" /><pair ddi="false" e1="DDI-PubMed.24509406.s9.e0" e2="DDI-PubMed.24509406.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24509406.s9.e0" e2="DDI-PubMed.24509406.s9.e1" /></sentence><sentence text=" Febuxostat 40 or 80 mg/day plus lesinurad 400 or 600 mg/day resulted in 100% of subjects achieving sUA &lt;6 mg/dl and up to 100% achieving sUA &lt;5 mg/dl"><entity charOffset="100-102" id="DDI-PubMed.24509406.s10.e0" text="sUA" /><entity charOffset="138-140" id="DDI-PubMed.24509406.s10.e1" text="sUA" /><pair ddi="false" e1="DDI-PubMed.24509406.s10.e0" e2="DDI-PubMed.24509406.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24509406.s10.e0" e2="DDI-PubMed.24509406.s10.e1" /></sentence><sentence text=" No clinically relevant changes in the PKs of either drug were noted" /><sentence text=" The combination was well tolerated" /><sentence text="" /><sentence text="The clinically important targets of sUA &lt;6 mg/dl and &lt;5 mg/dl are achievable in 100% of patients when combining lesinurad and febuxostat"><entity charOffset="112-121" id="DDI-PubMed.24509406.s14.e0" text="lesinurad" /><entity charOffset="126-136" id="DDI-PubMed.24509406.s14.e1" text="febuxostat" /><entity charOffset="36-45" id="DDI-PubMed.24509406.s14.e2" text="sUA" /><pair ddi="false" e1="DDI-PubMed.24509406.s14.e2" e2="DDI-PubMed.24509406.s14.e2" /><pair ddi="false" e1="DDI-PubMed.24509406.s14.e2" e2="DDI-PubMed.24509406.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24509406.s14.e2" e2="DDI-PubMed.24509406.s14.e1" /><pair ddi="false" e1="DDI-PubMed.24509406.s14.e0" e2="DDI-PubMed.24509406.s14.e0" /><pair ddi="false" e1="DDI-PubMed.24509406.s14.e0" e2="DDI-PubMed.24509406.s14.e1" /></sentence><sentence text="" /></document>